Drugs / Elasomeran
Elasomeran
also known as
mRNA 1273 · COVID-19 vaccine · Moderna COVID-19 vaccine · Spikevax · Moderna · COVID-19 Vaccine Moderna · Moderna mRNA-1273 · mRNA-1273 SARS-CoV-2 Vaccine · +16 more
Trials 59 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05397223 | May 2022 → Feb 2026 | COVID-19, cytomegalovirus infection, influenza, respiratory syncytial virus infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04889274 | May 2021 → Apr 2026 overdue | cardiovascular disorder | Queen Mary University of London | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04866069 | Apr → Sep 2021 | COVID-19 | Osman ERGANIS, PhD, Prof | Terminated | No outcome recorded |
| Phase 1 | NCT04785144 | Mar 2021 → Jul 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT04813796 | Mar 2021 → Jul 2023 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04283461 | Mar 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT06683352 | Nov 2024 → Jul 2025 | COVID-19, influenza | BioNTech SE | Completed | No outcome recorded |
| Phase 1/2 | NCT05375838 | May → Dec 2022 | COVID-19, influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT05280158 | Mar 2022 → Feb 2023 | Orthocoronavirinae infectious disease | University of California, Los Angeles | Terminated | No outcome recorded |
| Phase 1/2 | NCT05132855 | Nov 2021 → Apr 2023 | COVID-19 | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04889209 | May 2021 → Jun 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT04677660 | Jan 2021 → Feb 2022 | COVID-19 | Takeda | Completed | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT05315362 | May → Sep 2022 | COVID-19 | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT05289037 | Mar 2022 → Nov 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT05077254 | Dec 2021 → Feb 2024 | disease related to solid organ transplantation | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04977024 | Sep 2021 → Dec 2026 expected | COVID-19, leukemia, plasma cell myeloma | GeoVax, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04930770 | Sep → Dec 2021 | COVID-19 | Maria Joyera Rodríguez | Withdrawn | No outcome recorded |
| Phase 2 | NCT05000216 | Aug 2021 → Jun 2023 | juvenile dermatomyositis, juvenile idiopathic arthritis, pediatric multiple sclerosis, pediatric systemic lupus erythematosus +3 | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT04969263 | Aug 2021 → Nov 2022 | disease related to solid organ transplantation | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT05027672 | Jul → Aug 2021 | — | Ministerio de Salud de Ciudad Autónoma de Buenos Aires | Unknown | No outcome recorded |
| Phase 2 | NCT04852978 | Apr 2021 → Nov 2022 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04847050 | Apr 2021 → May 2023 | leukemia, plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT04761822 | Apr 2021 → Apr 2022 | COVID-19, hypersensitivity reaction disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04748471 | Feb → Jul 2021 | — | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2 | NCT04405076 | May 2020 → Oct 2021 | Orthocoronavirinae infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT05168813 | Dec 2021 → Apr 2024 | COVID-19, HIV infectious disease | COVID-19 Prevention Network | Completed | No outcome recorded |
| Phase 2/3 | NCT05022329 | Sep 2021 → May 2022 | COVID-19, chronic kidney disease | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded |
| Phase 2/3 | NCT05279365 | Jul 2021 → Aug 2022 | COVID-19 | DHR Health Institute for Research and Development | Unknown | No outcome recorded |
| Phase 2/3 | NCT04927065 | May 2021 → Nov 2023 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT04796896 | Mar 2021 → Mar 2024 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT04649151 | Dec 2020 → Jun 2024 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT05387317 | Apr 2024 → Jan 2025 | COVID-19 | Murdoch Childrens Research Institute | Withdrawn | No outcome recorded |
| Phase 3 | NCT05556720 | Dec 2022 → Jun 2026 overdue | B-cell chronic lymphocytic leukemia, HIV infectious disease, disease related to solid organ transplantation, plasma cell myeloma | Monash University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05119855 | Mar 2022 → Dec 2023 | COVID-19, human papilloma virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05158140 | Jan 2022 → Feb 2023 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05230953 | Jan 2022 → Jul 2024 | COVID-19 | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT05047770 | Oct 2021 → Aug 2022 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT05028257 | Sep 2021 → May 2023 | anaphylaxis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT04860297 | Apr 2021 → May 2023 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04811664 | Mar → Dec 2021 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04806113 | Mar → Jun 2021 | COVID-19, rheumatoid arthritis, systemic lupus erythematosus | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 3 | NCT04470427 | Jul 2020 → Dec 2022 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT07279766 | Dec 2025 → Aug 2026 overdue | COVID-19 | Tor Biering-Sørensen | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07266558 | Nov 2025 → Jun 2027 expected | COVID-19 | ModernaTX, Inc. | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05075538 | Dec 2021 → Jan 2024 | cancer | Jules Bordet Institute | Terminated | No outcome recorded |
| Phase 4 | NCT05107557 | Nov → Dec 2021 | COVID-19 | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT05104333 | Nov 2021 → Nov 2022 | pneumonia | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT05079633 | Sep → Oct 2021 | — | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04969250 | Aug 2021 → Dec 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT05012800 | Jul 2021 → Aug 2022 | — | Beijing 302 Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04952402 | Jul 2021 → Feb 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT06189040 | May → Nov 2021 | COVID-19 | University of Antwerp | Completed | No outcome recorded |
| Phase 4 | NCT04792567 | Apr → Sep 2021 | secondary progressive multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT04818736 | Apr → Sep 2021 | — | McMaster University | Withdrawn | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT06116669 | Nov 2023 → Dec 2024 | iron deficiency anemia | Swiss Federal Institute of Technology | Unknown | No outcome recorded |
| — | NCT04927936 | Jun 2021 → Sep 2022 | COVID-19 | Erasmus Medical Center | Unknown | No outcome recorded |
| — | NCT04900467 | May → Jul 2021 | — | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| — | NCT05019456 | Mar 2021 → Dec 2025 overdue | COVID-19, influenza | University of Arizona | Active not recruiting | No outcome recorded |
| — | NCT04715438 | Jan → Jun 2021 | cancer | University Medical Center Groningen | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 25 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05081271 Comparator | Oct 2021 → May 2022 | multiple sclerosis | Griffin Hospital | Terminated | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT05383560 Comparator | Sep 2022 → Jan 2024 | COVID-19 | Sheba Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05345873 Comparator | Jul → Oct 2022 | COVID-19 | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05197153 Comparator | Jan → Jun 2022 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 2 | NCT05137236 Comparator | Dec 2021 → Mar 2023 | Orthocoronavirinae infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05160766 Comparator | Nov 2021 → Oct 2022 | — | Oliver Cornely, MD | Completed | No outcome recorded |
| Phase 2 | NCT04988048 Comparator | Aug → Sep 2021 | COVID-19 | Ministry of Public Health, Argentina | Unknown | No outcome recorded |
| Phase 2 | NCT05324319 Comparator | Jun 2021 → Jul 2022 | COVID-19 | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2 | NCT04894435 Comparator | May 2021 → Nov 2024 overdue | COVID-19 | Canadian Immunization Research Network | Active not recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05236491 Comparator | Mar 2022 → Jun 2023 | overlapping connective tissue disease, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis +2 | Paul R Fortin | Unknown | No outcome recorded |
| Phase 2/3 | NCT05249829 Comparator | Feb 2022 → Jun 2023 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT06694389 Comparator | Nov 2024 → Nov 2025 | COVID-19, influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06354998 Comparator | Apr → May 2024 | Orthocoronavirinae infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06178991 Comparator | Dec 2023 → Nov 2024 | COVID-19, influenza | BioNTech SE | Completed | No outcome recorded |
| Phase 3 | NCT06097273 Comparator | Oct 2023 → May 2024 | Orthocoronavirinae infectious disease, influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05415267 Comparator | Jul 2023 → Dec 2026 expected | COVID-19 | Kirby Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT05543356 Comparator | May → Jul 2022 | COVID-19 | Murdoch Childrens Research Institute | Withdrawn | No outcome recorded |
| Phase 3 | NCT05228730 Comparator | May → Jul 2022 | COVID-19 | Murdoch Childrens Research Institute | Terminated | No outcome recorded |
| Phase 3 | NCT05048940 Comparator | Sep 2021 | COVID-19 | Marqués de Valdecilla Research Institute (IDIVAL) | Withdrawn | No outcome recorded |
| Phase 3 | NCT04805125 Comparator | Apr 2021 → Sep 2023 | immunodeficiency disease | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06441955 Comparator | Mar 2024 → Sep 2030 expected | long COVID-19 | Well- Konnect Healthcare Services and Research Firm | Recruiting | No outcome recorded |
| Phase 4 | NCT05030974 Comparator | Oct 2021 → Mar 2022 | COVID-19, kidney disorder | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 4 | NCT04885907 Comparator | May → Jul 2021 | COVID-19, immunodeficiency disease | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 4 | NCT04760132 Comparator | Feb 2021 → Dec 2023 | Orthocoronavirinae infectious disease | Jens D Lundgren, MD | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05074368 Comparator | Jul 2021 → Apr 2022 | — | National Taiwan University Hospital | Completed | No outcome recorded |
Press releases naming this drug 310 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-29 | Pfizer | European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union pfizer.com ↗ |
| 2026-07-29 | BioNTech SE | European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union biontech.com ↗ |
| 2026-04-18 | Sanofi | Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study sanofi.com ↗ |
| 2025-09-08 | Pfizer | Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula pfizer.com ↗ |
| 2025-09-08 | BioNTech SE | Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response with their LP.8.1-adapted COVID-19 Vaccine 2025-2026 Formula biontech.com ↗ |
| 2025-07-25 | Pfizer | Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union pfizer.com ↗ |
| 2025-07-25 | BioNTech SE | Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union biontech.com ↗ |
| 2025-05-28 | BioNTech SE | Pfizer and BioNTech Submit EMA Application for COVID-19 Vaccine Targeting LP.8.1 for 2025-2026 Season biontech.com ↗ |
| 2025-01-06 | ModernaTX, Inc. | Moderna – 2024 Shareholder Letter from CEO Stéphane Bancel modernatx.com ↗ |
| 2024-12-20 | ModernaTX, Inc. | Moderna – The Hidden Cost of COVID: Long COVID's Impact on the Workforce modernatx.com ↗ |
| 2024-12-12 | ModernaTX, Inc. | Moderna’s Commitment to Patient Access in the United States modernatx.com ↗ |
| 2024-09-20 | Pfizer | Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union pfizer.com ↗ |
| Show all 310 releases opens the full record — a long page | ||
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 91 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elasomeran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05543356 ↗ |
| Known as | Comirnaty Pfizer COVID19 vaccine | “Comirnaty Pfizer COVID19 vaccine” NCT05028257 ↗ |
| Known as | COVID-19 vaccine | “The COVID-19 vaccine was manufactured by Sinovac Research” NCT05107557 ↗ |
| Known as | COVID-19 vaccine (Vero cell), Inactivated | “This study is a randomized and controlled Phase IV clinical trial of the COVID-19 vaccine (Vero cell), Inactivated manufactured by Sinovac Research” NCT05107557 ↗ |
| Known as | COVID-19 Vaccine Moderna | “Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna)” NCT04930770 ↗2“mRNA-1273, COVID-19 Vaccine Moderna, mARN vaccine, administrated by intramuscular” NCT04900467 ↗ |
| Known as | CX-024414 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650491 ↗ |
| Known as | M-1273 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650491 ↗ |
| Known as | messenger RNA-1273 | “SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine” NCT05074368 ↗ |
| Known as | Moderna | “Participants ( n =273) with CKD not on dialysis or receiving dialysis were randomized 1:1 to third dose 30- µ g BNT162b2 (Pfizer-BioNTech) or 100- µ g mRNA-1273 (Moderna).” PMID 37847518 ↗ Oct 2023 |
| Known as | Moderna (mRNA-1273 or Spikevax) | “Moderna (mRNA-1273 or Spikevax)” NCT04988048 ↗ |
| Known as | Moderna Bivalent mRNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05556720 ↗ |
| Known as | Moderna COVID-19 vaccine | “Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)” NCT04805125 ↗8“mRNA-1273 (Moderna COVID-19 vaccine) 50 ug” NCT05280158 ↗ “Moderna COVID-19 vaccine (mRNA 1273)” NCT05079633 ↗ “mRNA-1273 (Moderna COVID-19 vaccine)” NCT07279766 ↗ “Moderna COVID19 vaccine” NCT05028257 ↗ |
| Known as | Moderna COVID-19 Vaccine 2023-2024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05077254 ↗ |
| Known as | Moderna covid-19 vaccine rna | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650491 ↗ |
| Known as | Moderna mRNA-1273 | “For dose 1 and 2, the currently available mRNA vaccines (Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273) are two dose vaccines which were studied in schedules of either 0 and...” NCT04894435 ↗ |
| Known as | Moderna mRNA-1273 COVID-19 vaccine | “Study-provided Moderna mRNA-1273 COVID-19 vaccine” NCT04952402 ↗ |
| Known as | mRNA 1273 | “Participants ( n =273) with CKD not on dialysis or receiving dialysis were randomized 1:1 to third dose 30- µ g BNT162b2 (Pfizer-BioNTech) or 100- µ g mRNA-1273 (Moderna).” PMID 37847518 ↗ Oct 202356“We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca) and/or mRNA (mRNA-1273, Moderna) vaccines.” PMID 35305895 ↗ Mar 2022 “The mRNA vaccine, mRNA-1273/TAK-919, encodes the prefusion-stabilised spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).” PMID 35177302 ↗ Feb 2022 “mRNA-1273 or Spikevax Moderna Switzerland GmbH and the National Institute of Allergy and Infectious Diseases (NIAID) of the United States.” NCT04988048 ↗ “The participants were assigned to receive no booster, an Ad26.COV2.S booster, an mRNA-1273 booster, or a BNT162b2 booster.” PMID 35045226 ↗ Jan 2022 “mRNA-1273 Injection (Drug Product) is an lipid nanoparticles (LNPs) dispersion containing a single mRNA sequence” NCT04847050 ↗ “Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna)” NCT04930770 ↗ “This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa” NCT05081271 ↗ “mRNA-1273, COVID-19 Vaccine Moderna, mARN vaccine, administrated by intramuscular” NCT04900467 ↗ “the vaccine produced by Moderna (mRNA-1273)” NCT05027672 ↗ “with mRNA-1273 (Moderna COVID-19) vaccine” NCT04818736 ↗ “COVID-19 (all ages: mRNA-1273) vaccines.” PMID 40332892 ↗ Jun 2025 “Moderna COVID-19 vaccine (mRNA 1273)” NCT05079633 ↗ “mRNA vaccine mRNA-1273” PMID 37321955 ↗ Jun 2023 “Spikevax (mRNA-1273)” NCT05160766 ↗ |
| Known as | mRNA-1273 SARS-CoV-2 Vaccine | “Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.” NCT04894435 ↗1“mRNA-1273 SARS-CoV-2 Vaccine” NCT05022329 ↗ |
| Known as | SARS-CoV-2 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04866069 ↗ |
| Known as | Spikevax | “single fractional dose of 20µg mRNA-1273 LNP vaccine (Spikevax, Moderna) more than 3 months after primary vaccination with Comirnaty (Pfizer) vaccine and/or after having...” NCT05315362 ↗7“For the Moderna SPIKEVAX Bivalent Original/Omicron BA.4/5: participants will receive one (1) intramuscular injection of 0.5 mL (50 mcg).” NCT05236491 ↗ “For this arm, the current variant formulation of Spikevax (mRNA-1273) vaccine will be used.” NCT07279766 ↗ “following mRNA-1273 (Spikevax™) vaccination” PMID 36376733 ↗ Nov 2022 |
| Known as | Spikevax (previously covid-19 vaccine moderna) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650491 ↗ |
| Known as | SPIKEVAX Bivalent Original/Omicron BA.4/5 | “For the Moderna SPIKEVAX Bivalent Original/Omicron BA.4/5: participants will receive one (1) intramuscular injection of 0.5 mL (50 mcg).” NCT05236491 ↗ |
| Known as | Spikevax Moderna vaccine | “Spikevax (Moderna) vaccine” NCT05048940 ↗ |
| Known as | Spikevax mrna | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650491 ↗ |
| Known as | TAK-919 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04677660 ↗ |
| Modality | Messenger RNA (mRNA) | “The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine” PMID 33378609 ↗ Dec 2020 |
| Route | Intramuscular | “Subjects will receive an intramuscular (IM) injection (0.5 milliliters \[mL\]) of mRNA-1273 on Days 1 and 29 in the deltoid muscle” NCT04283461 ↗ |